IKT_OUT_1 [2025-04-03 06:19:41 -0400] 3240 Bytes | 894 tokens | Cum: 894 tkns (11.18% of 8k)
==========================================================================

Listen up, partner—it's 6:19:40 AM on Thu Apr 03, 2025 -0400, and I’m revved up about Inhibikase Therapeutics (IKT), climbing from 2.18 to 2.6. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Inhibikase Therapeutics (IKT)
IPO: 2020-12-23 (4 Years Ago)
Market Cap: $151,905,037
Shares Outstanding: 74,340,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Here's the first list of news for Inhibikase Therapeutics:

C1 - Mar-27-25 04:01PM - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
C2 - Mar-05-25 09:55AM - Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
C3 - Feb-24-25 08:00AM - Inhibikase Announces Expansion of Senior Leadership Team
C4 - Feb-18-25 08:00AM - Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
C5 - Nov-14-24 08:37AM - Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
C6 - Oct-23-24 06:31AM - Inhibikase Therapeutics Secures Funding and Strengthens Leadership
C7 - Oct-22-24 09:07PM - Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc
C8 - Oct-21-24 09:05AM - Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Prior AI Reports for IKT:
1. 2025-04-02 – Score: 35 – Target: 2.5000 – Highs: 2.2650 / – / –
financial-distress-looms-as-companys-performance-metrics-plunge
2. 2025-04-01 – Score: 1 – Target: 2.5500 – Highs: 2.2300 / 2.2650 / –
challenging-times-ahead-with-negative-roe-and-sales-drop

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Inhibikase Therapeutics (IKT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

IKT_OUT_3 [2025-04-03 06:19:44 -0400] 1112 Bytes | 313 tokens | Cum: 1209 tkns (15.11% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity**
Date: Mar-27-25 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/27/3050975/0/en/Inhibikase-Therapeutics-Announces-2024-Financial-Results-and-Highlights-Recent-Activity.html

March 27, 2025 16:01 ET| Source:Inhibikase TherapeuticsInhibikase Therapeutics

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the year ended December 31, 2024 and highlighted recent developments.

“The financing concluded in October positioned us to focus our clinical development efforts on advancing IkT-001 toward a late-stage clini

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IKT_OUT_5 [2025-04-03 06:19:45 -0400] 795 Bytes | 248 tokens | Cum: 1524 tkns (19.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-29T17:50:47Z - Inhibikase Therapeutics (NYSE:IKT) Earns "Neutral" Rating from HC Wainwright...
A2 - 2025-03-27T21:05:14Z - Inhibikase Therapeutics GAAP EPS of -$1.16 (IKT:NASDAQ)...
A3 - 2025-03-27T20:27:27Z - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity...
A4 - 2025-03-18T05:46:08Z - Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.9% - What's Next?...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IKT_OUT_7 [2025-04-03 06:19:52 -0400] 1098 Bytes | 340 tokens | Cum: 1866 tkns (23.33% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Inhibikase Therapeutics (NYSE:IKT) Earns "Neutral" Rating from HC Wainwright**Date: 2025-03-29Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/inhibikase-therapeutics-nyseikt-earns-neutral-rating-from-hc-wainwright-2025-03-28/Shares of NYSE:IKT traded down $0.18 during trading on Friday, hitting $2.20. 40,320 shares of the company's stock traded hands, compared to its average volume of 171,426. The company has a 50-day moving average price of $2.43 and a 200-day moving average price of $2.38. Inhibikase Therapeutics has a 52 week low of $1.12 and a 52 week high of $4.20. The company has a market cap of $152.25 million, a price-to-earnings ratio of -0.82 and a beta of 1.04.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stifel Financial Corp acquired a ne

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IKT_OUT_9 [2025-04-03 06:19:53 -0400] 1083 Bytes | 317 tokens | Cum: 2353 tkns (29.41% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-20T20:45:00Z - Top 10 Small-Cap Stocks to Watch in 2025
B2 - 2024-06-17T12:05:00Z - Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
B3 - 2024-06-05T12:05:00Z - Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
B4 - 2024-05-20T12:01:00Z - Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
B5 - 2024-05-16T00:00:00Z - Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
B6 - 2024-05-15T12:45:00Z - Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IKT_OUT_11 [2025-04-03 06:19:56 -0400] 556 Bytes | 159 tokens | Cum: 2514 tkns (31.42% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Top 10 Small-Cap Stocks to Watch in 2025**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/top-10-smallcap-stocks-to-watch-in-2025-200655548The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IKT_OUT_13 [2025-04-03 06:19:57 -0400] 1070 Bytes | 256 tokens | Cum: 2831 tkns (35.39% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes to...

S2 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes to...

S3 - 2025-03-27 8-K Item2.02. Results of Oper and Fin Cond.

On March 27, 2025, Inhibikase Therapeutics, Inc. announced its financial results for the year ended December 31, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being f...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IKT_OUT_15 [2025-04-03 06:20:01 -0400] 1098 Bytes | 215 tokens | Cum: 3048 tkns (38.10% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report. This discussion and analysis and other parts of this Annual Report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those se

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

IKT_OUT_17 [2025-04-03 06:20:13 -0400] 4593 Bytes | 1320 tokens | Cum: 4453 tkns (55.66% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------------+
| Volume: 140,910 | Perf Month: -0.91% | Option/Short: No / Yes | Sales Y/Y TTM: -100.00% |
+---------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 174.44K | Perf Quarter: -32.72% | Short Float: 2.86% | ROE: -52.00% |
+---------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 0.81 | Index: - | Short Ratio: 7.47 | ROI: -29.01% |
+---------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 43.36 | Market Cap: 162.06M | Short Interest: 1.30M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.20 | Shs Outstand: 69.36M | Beta: 1.03 | EPS Surprise: 1114.99% |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA20: -3.50% | Shs Float: 45.53M | Sales Q/Q: -100.00% | P/E: - |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA50: -8.88% | Inst Own: 52.65% | Sales past 5Y: 44.23% | Earnings: Mar 27 BMO |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA200: 5.23% | Insider Own: 38.76% | Employees: 16 | |
+---------------------+-----------------------+------------------------+-------------------------+
| Perf Week: -8.79% | Insider Trans: 7.34% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

No transactions recorded.

Inside Trans: Inhibikase Therapeutics, Inc. (IKT) by Iwicki Mark T (Chief Executive Officer) on 2025-02-21
- Stock Option (Right to Buy): 602346 shares at $0 (D)

Inside Trans: Inhibikase Therapeutics, Inc. (IKT) by Aurentz Vincent (Unknown Title) on 2025-02-21
- Stock Option (Right to Buy): 134427 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -27519886.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.18
Average Volume: 134391.27
30-Day High: 2.47
30-Day Low: 1.96

[Detailed Financials: TTM 2024]
- Total Assets: $98,599,846.0
- Total Liabilities: $3,733,566.0
- Total Equity: $94,866,280.0
- Current Assets: $98,451,309.0
- Current Liabilities: $3,733,566.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.16

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $47,325,400.0

[Detailed Financials: FY 2024]
- Total Assets: $98,599,846.0
- Total Liabilities: $3,733,566.0
- Total Equity: $94,866,280.0
- Current Assets: $98,451,309.0
- Current Liabilities: $3,733,566.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.16

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $47,325,400.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

IKT_OUT_19 [2025-04-03 06:20:15 -0400] 676 Bytes | 167 tokens | Cum: 4921 tkns (61.51% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

IKT_IN_21 [2025-04-03 06:20:16 -0400] 126 Bytes | 29 tokens | Cum: 4978 tkns (62.22% of 8k)
==========================================================================

====================================
[2025-04-03 06:20:16] # Analysis Completed
Elapsed Time: 36.49 seconds